Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis

Fig. 5

Effect of combined therapy with AD-MSCs and a pentavalent antimonial on clinical profile. C57BL/6 mice were inoculated in the footpad with Leishmania amazonensis. On days 15 and 21 post-infection, the AD-MSC and AD-MSC + PA groups received AD-MSC and the control group was injected with PBS. On day 18, the PA and AD-MSC + PA groups started treatment with meglumine antimoniate, administered on alternate days until day 50 post-infection. After 52 days, the mice were euthanized and the parasite load was determined by limiting dilution. a Analysis of lesion progression. b Analysis of parasite load in the footpad. c Analysis of parasite lode in the popliteal lymph node. N = 9 in the PBS group and N = 6 in the other groups. Values show the mean ± standard deviation. *P < 0.05, **P < 0.01, and ***P < 0.005 indicate a significant difference between the groups in relation to the control (PBS); #P < 0.05 and ##P < 0.01 indicate a significant difference between the groups in relation to the AD-MSC; +P < 0.05 indicates a significant difference in the AD-MSC group in relation to the PA group

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512